Shaanxi Meibang Pharmaceutical Group Co Ltd (605033) — Capital Reinvestment Ratio

Latest as of September 2025: 0.19x

Shaanxi Meibang Pharmaceutical Group Co Ltd (605033) has a Capital Reinvestment Ratio of 0.19x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥281.88 Million) in capital expenditures (CN¥54.40 Million). Check Shaanxi Meibang Pharmaceutical Group Co tangible equity quality to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.19x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥281.88 Million
CNY

Capital Expenditures

CN¥54.40 Million
CNY

Data as of

Sep 2025
Most recent filing

Shaanxi Meibang Pharmaceutical Group Co Ltd Capital Reinvestment Ratio (2017–2024)

This chart tracks Shaanxi Meibang Pharmaceutical Group Co Ltd's Capital Reinvestment Ratio across 7 annual periods. For the full cash flow conversion analysis, see Shaanxi Meibang Pharmaceutical Group Co (605033) cash conversion ratio.

Annual Capital Reinvestment Ratio for Shaanxi Meibang Pharmaceutical Group Co Ltd (2017–2024)

Year-by-year Capital Reinvestment Ratio for Shaanxi Meibang Pharmaceutical Group Co Ltd from 2017 to 2024. See Shaanxi Meibang Pharmaceutical Group Co free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2024 0.57x CN¥280.40 Million CN¥158.81 Million ▼ -6.9%
2023 0.61x CN¥334.79 Million CN¥203.69 Million ▼ -29.6%
2022 0.86x CN¥126.41 Million CN¥109.29 Million ▲ +4.9%
2020 0.82x CN¥74.88 Million CN¥61.71 Million ▲ +213.4%
2019 0.26x CN¥128.45 Million CN¥33.78 Million ▼ -87.2%
2018 2.06x CN¥16.96 Million CN¥34.86 Million ▲ +244.2%
2017 0.60x CN¥29.41 Million CN¥17.56 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow